Revive Therapeutics (TSE:RVV) has released an update.
Revive Therapeutics Ltd. reports positive progress in its clinical study on the use of psilocybin to treat methamphetamine use disorder, with encouraging initial efficacy results and nearly half of the intended participants enrolled. The study’s findings are expected to bolster future clinical research and commercial strategies, specifically in regions where psilocybin is permitted for medical use. Revive Therapeutics is also focusing on the development of a unique psilocybin delivery system via a microneedle patch for neuropsychiatric conditions.
For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.
